Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003050 · ClinicalTrials.gov registry record · Phase 2
Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer
A Phase 2 study, sponsored by University of Southern California.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT00003050 is a Phase 2 study that has completed, run by University of Southern California. The registered enrollment target is 46 participants.
The verdict
NCT00003050, a Phase 2 study, has completed, sponsored by University of Southern California.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of radiation therapy plus paclitaxel in treating patients with stage IIB or stage III breast cancer.
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- DRUG doxorubicin hydrochloride
- DRUG tamoxifen citrate
- PROCEDURE surgical procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1997-04 |
| Est. Completion | 2000-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003050
The ClinicalTrials.gov registry entry for NCT00003050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003050 about?
NCT00003050 is a clinical study titled "Radiation Therapy Plus Paclitaxel in Treating Patients With Stage IIB or Stage III Breast Cancer". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effe...
What is the current status of trial NCT00003050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 1997-04. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00003050?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG), surgical procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00003050?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.